PAK1-blockers: Potential Therapeutics against COVID-19

Medicine in Drug Discovery

Hong He¹  Hiroshi Maruta² 

[1] Corresponding author.;PAK Research Center, Melbourne, Australia;

关键词: PAK1;    pathogenic kinase;    viral infection;    COVID-19;    cancer;   

DOI  :  

来源: DOAJ

【 摘 要 】

ABSTRACT: PAK1 (RAC/CDC42-activated kinase 1) is the major “pathogenic” kinase whose abnormal activation causes a wide variety of diseases/disorders including cancers, inflammation, malaria and pandemic viral infection including influenza, HIV and COVID-19. Since Louis Pasteur who developed a vaccine against rabies in 1885, in general a series of “specific” vaccines have been used for treatment of viral infection, mainly because the majority of pre-existing antibiotics are either anti-bacterial or anti-fungal, thereby being ineffective against viruses in general. However, it takes 12–18 months till the effective vaccine becomes available. Until then ventilator (O2 supplier) would be the most common tool for saving the life of COVID-19 patients. Thus, as alternative potentially more direct “broad-spectrum” signalling mechanism–based COVID-19 therapeutics, several natural and synthetic PAK1-blockers such as propolis, melatonin, ciclesonide, hydroxy chloroquine (HQ), ivermection, and ketorolac, which are readily available in the market, are introduced here.

【 授权许可】

Unknown